Argos Therapeutics Inc (NASDAQ:ARGS) is an immuno-oncology company that specializes on the development and commercialization of a variety of immunotherapies for the treatment of HIV, cancer and other infectious diseases utilizing it’s Arcelis® technology platform. The stock jumped 30.44% on positive results from positive data released from an HIV study.

Wednesday morning the company reported immunogenicity data from a study of AGS-004 dendritic cell therapy in patients with HIV. The study was conducted at the University of North Carolina and Duke University using six patients with acute HIV infection. The study hit its primary end goal with all six patients showing a positive immune response.

Charles Nicolette, Chief Scientific Officer stated, “We are encouraged by the results of this study, in which AGS-004 generated a targeted immune response against the HIV virus.” He continued saying, “This is an important first step in our goal of not only combating active HIV infection, but also of eliminating the HIV viral reservoir, which has not yet been achieved with any currently available agent or combination therapy.

Argos will now look to increase the number of patients to 12 and plan to report initial data by early 2018. The company has already secured funding for the development of AGS-004 for its HIV treatment from the National Institutes of Health and the Collaboratory of Research for AIDS Eradication.